High Level Software Solutions to Conducting Research in the Spine Biologics Field
One of the most promising areas of research and development in the field of biologics is spine biologics, regenerative therapies designed for spinal cord injuries. Not only have there been significant scientific advances spine biologics technologies and capabilities, but a recent report also predicts rapid market growth over the next five years, especially in North America. For life science companies that are looking to take advantage of the boom in the spine biologics field, ensuring research efficiency and reducing operational costs will be key. Therefore, using software that supports product design and cuts down on the time to market can help companies make the most of the current market environment.
Scientific Advances in the Field of Spine Biologics
Spine biologics are utilized in spinal fusion surgeries. By stimulating bone growth formation in the inflammatory stage, the repair stage and the remodeling stage, spine biologics can assist in the treatment of a wide variety of medical conditions, ranging from traumatic spinal cord injuries to cancerous tumors to degenerative disc disease. In the past, autografts were used in spinal fusion surgeries, but they are increasingly being replaced by biologics-based allografts, which are less likely to cause pain, initiate infection and weaken bone.1 Some of the most promising areas of development in the spine biologics field include:
- Bone graft substitutes
- Cell-based matrices
- Demineralized bone matrices
Market Growth in the Spine Biologics Field
Alongside these scientific advances, market growth in spine biologics has been increasing, and a March 2017 report from Allied Research indicates that expansion will only continue over the next five years. According to the report, the spine biologics market was already at $1,644 million in 2015, and it is expected to reach $2,214 million by 2022, which equates to a compound annual growth rate (CAGR) of 4.3 percent. Currently, bone graft substitutes account for the greatest share of the market, but the cell-based matrices segment is predicted to have the fastest growth rate in the next five years: an estimated CAGR of 5.9 percent.2
There are several factors that are driving growth in the field. Perhaps most significant have been the advances in spine biologics research, which have expanded the range of possible allografts and improved the effectiveness of spine biologics. Also, newly developed spine biologics cut down on postoperative time and promote faster recovery. That is ideal due to the growing size of the geriatric population in the United States, making spinal fusion surgery more frequent. Indeed, North America currently accounts for about two-thirds of the spine biologics market, and it is expected to maintain market dominance over the next five years.
Challenges in Spine Biologics Research and Development
Despite the promising spine biologics market, the Allied Research report also identifies a few key challenges that life science companies will need to overcome in order to achieve market success. Specifically, reimbursement scenarios can be unfavorable, and bone grafts present higher costs than traditional autografts.This means that during development, operational cost savings will be essential. Modern software solutions can help researchers accomplish this aim by improving research efficiency, which lowers development costs and increases the likelihood that spine biologics research and development will ultimately be a good business decision for the organization.
Another objective for life science companies looking to get into spine biologics will be right-first-time therapeutics design. Given the potential financial pitfalls in the industry, companies cannot afford to invest in a potential treatment, only to have it be rejected during clinical trials.
Despite the complex regulatory environment for biologics, the March 2017 approval of a clinical trial for a spine biologic therapy serves as a positive sign for other treatments in the pipeline. The sponsor company, Burst Biologics, received approval to begin clinical trials on its BioBurst cellular allograft in spinal fusion patients. According to the company spokesperson, the initial prospective trial will include 450 patients at 15 study sites across the United States. If the technology makes it through clinical trials, it could be an exciting innovation in the field. However, even BioBurst recognizes that there are still questions regarding the mechanisms that lead to successful fusion. Modern software may be able to help organizations answer some of these questions before bringing products to clinical trials, making it less likely that they will fail before reaching the market.
BIOVIA Designed to Cure is a high-level software solution that can support the development of novel therapeutics from the earliest stages of research to their introduction on the market. By improving research efficiency and facilitating market-based decision making, this software can help your company make the most of scientific advances in spine biologics and the associated boon in the market. Contact us today to learn more about this and our other software offerings!
- “Biologics for Spine: Where We Are,” 2017, https://www.spine-health.com/physicians/biologics-spine-where-we-are-now ↩
- “Global Spine Biologics Market Expected to Reach $2,214 Million by 2022 – Allied Market Research,” March 22, 2017, http://www.orthospinenews.com/global-spine-biologics-market-expected-to-reach-2214-million-by-2022-allied-market-research/ ↩